Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 804-810

  Bulik, Catharine C ^a   Christensen, Henry ^a   Li, Peng ^a   Sutherland, Christina A ^a   Nicolau, David P ^a   Kuti, Joseph L ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CARBAPENEMASE; MEROPENEM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME SYNTHESIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 75749095558     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01190-09     Document Type: Article

References (28)

1. Bradford, P. A., S. Bratu, C. Urban, M. Visalli, N. Mariano, D. Landman, J. J. Rahal, S. Brooks, S. Cebular, and J. Quale. 2004. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenemhydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 39:55-60.
2. Bratu, S., P. Tolaney, U. Karumudi, J. Quale, M. Motty, S. Nichani, and D. Landman. 2005. Carbapenamase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Agents 56:128-132.
3. Craig, W. A., S. Kethireddy, D. R. Andes, T. Stamstad, K. Marchilo, J. Asbeck, and R. N. Jones. 2008. Impact of KPCs on the in vivo activity of three carbapenems in the neutropenic mouse-thigh infection model. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-029.
4. Crandon, J. C., C. C. Bulik, and D. P. Nicolau. 2009. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4352-4356.
5. Deshpande, L. M., P. R. Rhomberg, H. S. Sader, and R. N. Jones. 2006. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC program (1999-2005). Diagn. Microbiol. Infect. Dis. 56:367-372.
6. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36(Suppl. 1):S42-S50.
7. Drusano, G. L., F. Sorgel, J. Quinn, B. Mason, and D. Melnick. 2005. Impact of pharmacodynamic dosing of meropenem on emergence of resistance during treatment of ventilator-associated pneumonia (VAP): a prospective clinical trial. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. K-127.
8. Elkhaili, H., S. Niedergang, D. Pompei, L. Linger, K. Leveque, and F. Jehl. 1996. High-performance liquid chromatographic assay for meropenem in serum. J. Chromatogr. B. 686:19-26.
9. KPC-containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA. J. Antimicrob. Chemother. 63:427-437.
10. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
11. Hussein, K., H. Sprecher, T. Mashiach, I. Oren, I. Kassis, and R. Finkelstein. 2009. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30:666-671.
12. Kuti, J. L., P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau. 2003. Use of a Monte Carlo simulation to design an optimized pharamcodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123.
13. Landman, D., S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob. Chemother. 60:78-82.
14. Landman, D., S. Bratu, and J. Quale. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol. 58(Pt 10):1303-1308.
15. Li, C., J. L. Kuti, C. H. Nightingale, and D. P. Nicolau. 2006. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46:1171-1178.
16. Li, C., X. Du, J. L. Kuti, and D. P. Nicolau. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother. 51:1725-1730.
17. Livermore, D. M. 2001. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47:247-250.
18. Maglio, D., C. Ong, M. A. Banevicius, Q. Geng, C. H. Nightingale, and D. P. Nicolau. 2004. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob. Agents Chemother. 48:1941-1947.
19. Mattoes, H. M., J. L. Kuti, G. L. Drusano, and D. P. Nicolau. 2004. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. 26:1187-1198.
20. Nicasio, A. M., K. J. Eagye, D. P. Nicolau, E. Shore, M. Palter, J. Pepe, and J. L. Kuti. 2009. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J. Crit. Care [Epub ahead of print.] doi:10.1016/j.jcrc.2009.02.014.
21. Nordmann, P., G. Cuzin, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
22. Noyal, M. J. C., G. A. Menezes, B. N. Harish, S. Sujatha, and S. C. Parija. 2009. Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria. Indian J. Med. Res. 129:707-712.
23. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
24. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
25. Rhomberg, P. R., L. M. Deshpande, J. T. Kirby, and R. N. Jones. 2007. Activity of meropenem as serine carbapenemases evolve in US medical centers: monitoring report from the MYSTIC program (2006). Diagn. Microbiol. Infect. Dis. 59:425-432.
26. Smith Moland, E., N. D. Hanson, V. L. Herrera, J. A. Black, T. J. Lockhart, A. Hossain, J. A. Johnson, R. V. Goering, and K. S. Thomson. 2003. Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. 51:711-714.
27. Woodford, N., P. M. Tierno, K. Young, L. Tysall, M. I. Palepou, E. Ward, R. E. Painter, D. F. Suber, D. Shungu, L. L. Silver, K. Inglima, J. Kornblum, and D. M. Livermore. 2004. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lacatamase, KPC-3, in a New York medical center. Antimicrob. Agents Chemother. 48:4793-4799.
28. Yigit, H., A. M. Queenan, G. J. Anderson, A. Domenich-Sanchez, J. W. Biddle, C. D. Steward, S. Alberti, K. Bush, and F. C. Tenover. 2001. Novel carbapenemase-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45: 1151-1161.